What is the role of brentuximab vedotin in the treatment of Hodgkin lymphoma (Hodgkin disease)?

Updated: Sep 12, 2018
  • Author: Bradley W Lash, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

Brentuximab vedotin was approved by the US Food and Drug Administration (FDA) in August 2011 for treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplantation or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not candidates for a stem cell transplant. This agent is a CD30-directed antibody-drug conjugate consisting of IgG1 antibody cAC10, specific for human CD30, and the microtubule disrupting agent, monomethyl auristatin E (MMAE, or vedotin). [95]

Results from a study of patients with Hodgkin lymphoma in whom autologous stem cell transplantation and a median of four chemotherapy regimens had failed (n = 102) showed that 73% (95% confidence interval [CI], 65-83%) achieved an objective response to brentuximab vedotin therapy, including 32% with complete remission (95% CI, 23-42%) and 40% with partial remission (95% CI, 32-49%). Response duration averaged 6.7 months (range, 1.3-21.9 months). [96]

Current NCCN guidelines recommend brentuximab vedotin as maintenance therapy for 1 year after high-dose therapy with autologous stem cell rescue (HDT/ASCR). In addition, in selected patients, brentuximab vedotin can be used as second-line therapy prior to HDT/ASCR to minimize the use of more intensive chemotherapy. [4]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!